SoFi Invest
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
MaxCyte is a medical devices business based in the US. MaxCyte shares (MXCT) are listed on the NASDAQ and all prices are listed in US Dollars. MaxCyte employs 84 staff and has a trailing 12-month revenue of around $42 million.
SoFi Invest
tastyworks
Latest market close | $5.77 |
---|---|
52-week range | $3.36 - $7.76 |
50-day moving average | $5.68 |
200-day moving average | $5.52 |
Wall St. target price | $11.67 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-0.17 |
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $5.77 from 2023-01-27
1 week (2023-01-20) | 8.26% |
---|---|
1 month (2022-12-28) | 16.57% |
3 months (2022-10-28) | -17.69% |
6 months (2022-07-28) | 5.68% |
1 year (2022-01-28) | -4.63% |
---|---|
2 years (2021-01-24) | N/A |
3 years (2020-01-24) | N/A |
5 years (2018-01-24) | N/A |
Revenue TTM | $42 million |
---|---|
Gross profit TTM | $30.2 million |
Return on assets TTM | -5.66% |
Return on equity TTM | -9.12% |
Profit margin | -56.29% |
Book value | $2.50 |
Market capitalisation | $566.9 million |
TTM: trailing 12 months
We're not expecting MaxCyte to pay a dividend over the next 12 months.
Over the last 12 months, MaxCyte's shares have ranged in value from as little as $3.36 up to $7.76. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while MaxCyte's is 0.7024. This would suggest that MaxCyte's shares are less volatile than average (for this exchange).
To put MaxCyte's beta into context you can compare it against those of similar companies.
MaxCyte, Inc. , a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland. .
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.